ORTX - Earnings call transcript Q2 2019 | Orchard Therapeutics plc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Orchard Therapeutics Second Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, there will be a question and answer session and instructions will follow at that time. [Operator instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Renee Leck, Director of Investor Relations. begin. may you Ma'am,

Renee Leck

morning, Update. welcome Good Quarter Orchard's XXXX Investor everyone, operator. to and Second Thanks,

access for can Sections You slides of the going our Investor's to website, Orchard-TX.com. today's call by

XXF, a everyone started, implied uncertainties, the like on get by call statements as forward-looking could and we include Actual result will that those with form differ including most we set Before materially this to forward-looking remind from we risk that I'd that make events and results of statements. and any factors statements SEC in expressed those forth recent filings any filed the various other make. may or

In any to update views as specifically relied addition, call obligation upon this of subsequent disclaim statements our any any revise not represent on views as be date. only representing any We of our today statements. forward-looking forward-looking made or as and should

the CEO, to that, over our I'll with and turn President And call Rothera. Mark

Mark Rothera

is After our on X-Linked our programs and Disease, Wiskott-Aldrich be to These in Granulomatous time I or some Thanks, recent primary X-CGD. of or metachromatic deficiencies two WAS, spend immune Syndrome, using and are today's their or we'll a enjoying hope programs follow Renee. activities, leukodystrophy, our Chronic review call Welcome, everyone that and summer. ADA-SCID in lead MLD.

as Orchard's therapy you Before gene use we stem get started, scientific minutes or spend vision and HSC, about our a I'd reminding like to platform. hematopoietic cell, few of our

genetic diseases to We from rare, patients potentially the to are approach world. curative suffering a focused and a a gene deliver singular vision with pure-play therapy company life-threatening, around therapies

ex-vivo diseases demonstrated of platform physiological across developing concept in in HSC autologous lies a has different gene proof approach three systems. five that expertise therapies, Our

treated expression our achieved, children upon therapies, expand lifelong once our gene see gene-modified of sustained therapies. potential cells benefit we the and in therapeutic with for of engraftment potential are curative To the

and for MLD on first the on two vision half way regulatory delivering year. track of ADA-SCID this toward with We are on next for our well filings

primary you, XXX across immune one our durability remind disorders, over data sets believe hemoglobino or franchises: the have our most and of eight neurometabolic of clinical follow-ups response treated robust the to deficiencies, To portfolio and field we and we more, showing pathies. in programs With cover out gene going years comprehensive of three therapy. patients

RMAT close turning to proud to a that EMA the evidence review opportunity also program. dialogue FDA the recognizes Now, designation for of we've this week, strength frequent this and for so in were unmet granted generated the us far. the which third track XXXX. clinical with FDA on news, FDA the WAS, disease, have need RMAT and and recent enables for process medical expedited the to our program registrational both we and designation last our in designation This an is in filings announce for

franchise, May MPS-X Within continue Tiget. neurometabolic news Raffaele San momentum from end-licensing build to program our our our at we and a clinical-stage announcing Ospedale the partners the of from in

have MLD from SSIEM, announce early two Study at MPS-X September. in the Society in the oral programs Errors for to pleased Inborn are abstracts Metabolism accepted been in We and that as known of for Meeting, our presentations of

Investigators complete this program are For in in on proof-of-concept Tiget presenting XXXX. from will enrollment and and to of ongoing results treat half be the MPS-X, the to first updated trial. patients continuing is identify track

well trial, to from pivotal presentation set the integrated MLD, go XX-patient expanded will access an as results from registrational March presented as the beyond data programs. patients mined For in the of set cover

and by the in five condition, a remind of patients is of that's cessation motor of clinical in treated resulting the you, most a years, age cognitive The in which to the to out severe enough in results form. death early of often This their function, by extend eight for progression characterized shown the XXL-XXX, disease. devastating neurodegeneration loss have

this therapy first is of around as Europe is patients track possible. to for Our approved the on goal for half And get in XXXX. initial our the world rapidly regulatory filing as

to in to a on of global Italy. presence Now, establishing therapies. we Germany, a scale in have our commercialize commercial Orchard well and MLD, and launches the preparing in America up potential of growing with future and operations success crucial set where established Europe in in the is North gene process work leadership is This are ADA-SCID, France, and way our under

and Within East, America, Turkey, few plan Latin Asia. the next years, we to expand the into Middle also

such access, to advocacy, therapies. We key in hires have also as market patient and knowledge our of access promote global functions made diagnostics, and to

first treatments these Some that we potential and targeting. the the for gene Therefore, of healthcare communities therapies are place. are they professionals in diseases diseases see patient ensure for effective pathways new represent with impetus diagnostic in to our

to expect in also are chain. treatment are putting in We supply first well-controlled a launch countries the establishing place where and we centers

So beyond beta-thalassemia, and alluding in pipeline, our we recently a transfusion-dependent proof-of-concept. indications, achieved clinical-stage pipeline earlier have deep the Bates programs includes lead to stage which X-CGD that

We these programs, designing are with trials CMC now and registrational turning our engaging development for regulators attention focused to the work work. process undertaking of commercially

to I continue proud the as remaining and So team am on has been year we year. strategy tremendous XXXX of a really of deliver our for and milestones execution the

Bobby spend about of our WAS Chief our on are results our financial to gene and to relation Thomas, our investigational return Officer, together, Officer milestones. thinking agenda. rest S-CGD. some upcoming and the on we to commentary second-quarter therapy. Gaspar, review then with in in use I'll Business time and following value will we'll how some our addition Chief Financial the Officer, Frank For Scientific manufacturing, Chief time will close

So to you. Bobby, over

Bobby Gaspar

about year the We're first of initial Mark. tremendous by that excited a MLD team. work amount very ADA-SCID in their and result approaching Thank of lead is programs you, our regulatory the next and our half of filings in are

we my spent little have really time, for benefit on less area of the time we to to as to I where excited opportunity manufacturing, majority gene but focus the arena. by our very on and are commercial to immunodeficiencies into we primary investigational of today, plan see which a two topic I want we important WAS patients. a move However, previously therapies also equally touch X-CGD, would as the where like the

let's start with manufacturing. So

Our manufacturing commercial three and handles most drug the manufacturing advanced Oxford programs, MLD, for BioMedica in ADA-SCID, will as and CMO ADA-SCID. WAS network for the well. the vector clinical Lonza, product for place trials use ongoing manufacturing,

Molmed these For both MLD and WAS, functions. manages of

characteristics X-CGD manufacturing cost drug the to ahead consistency. as the and Looking transfusion-dependent will such of and help the process reduce and to improve product optimize programs ability beta-thalassemia, goods

progress late We the space the of our ongoing this use drug year with license the using work was for transduction programs. with SIRION enhancers making in This good for LentiBOOST technology agreement to last by are product. exemplified the manufacturer of certain

aspects We way vectors many are are different process. the lentiviral at we make we and the also automating looking of transduction improving

proud goal that have future to implementing and I'm efforts been of with these support and innovations we developments note at to and research the Orchard, these expanding our discovery trials programs.

planning open facility and and both also the vector of for we is manufacture. California, in under is work product which track remain intended way in are We to drug on our well Design XXXX. Fremont buildout

across products greater they these processes to developments to for All multiple be future and I optimal you our in manufactured a detail of can discussing highlights time forward this develop diseases. so with our patient scale serve at at commitment look populations point. global

for treatment the we talk the I about provide to received on designation, want about release OTL-XXX Wiskott-Aldreth Syndrome. additional some of issued now we for to which Now, press information RMAT recent WAS. the

nature evidence of stem In an addition far, current can morbidity, carry for potential care address to and FDA, the generated a facilitating recognizes is The bleeding also graft a and the WAS, mortality existing severe immunodeficiency indicates needs. dialogue allogeneic disorder, well with the designation as versus unmet the transplant, the cell need standard host which close of hematopoietic so this as OTL-XXX, population. The to of of RMAT risks has life-threatening as this these disease. such designation significant clinical

platelet system WAS presents with severe abnormalities. and immune

mortality trial and the showing clinical major episodes severe All patients areas. OTL-XXX highest clinical cause the alive the of improvements for infections. So disease, the are severe and eight aspects significant in treated bleeding these of in We registrational consequently their of are platelet are two in infections OTL-XXX post-treatments life-threatening and pre- patients is no treated bleeding an and This to follow-up. of frequency had with patients severe increase the eight due counts. episodes with years and severe measured to in bleeding episodes up and

episode related negligible of showed reduction severe with The improvement is to function, immunoglobulin in This the vaccine-specific the correction responses. a immune post-gene infections patients improved also and production, lymphocyte therapy. frequency in proliferation, including of significant an

by trial We reporting patients of the the year. primary all this be on end-point will data the end three-year in

by opportunity OTL-XXX will and enroll The application is for gives a initiated studies. guidance. manufacturing RMAT additional a cryopreserved cryo of designation on In strategy, this need first product, the with our line which to who product the study drug with have and consistent study be XXXX also engage forward the for FDA patients our indication, for track bridging BLA Molmed, is commercial In XXXX. commercial we manufacturer the with to study without the summary, well. manages the us submit vector this formulation extremely real the in half moving six

MMA timeframe. also application within to We in submit an Europe this plan

decreased been the at lifetime disease x-linked a living adolescence transplant, have our a description. indication their Best with individuals I the result, greater who late sustained X-CGD, patients such damage lungs high-risk was to design XX% now who we registrational as all turn, to adults. where Indeed, or seven for proof-of-concept and of CGD many have last functional more, in hospitalizations, current infections chronic patients, chronic the have want There which of and care. These candidates and clinical date antibiotic than clinical to a the from end results in of infections. an granulomatous to OTL-XXX six, the is neutrophils as fit out had are of where six all turn and usage, leading to allogeneic liver. This year. trial shown in in demonstrated benefited patients an for study standard months evaluable become seen of improvements XX

the XXXX which orphan registrational Japan. are with this XXXX patients, the often upcoming initially. designing over living coincides data, on that study an published the of are reimburse and this well is many prevalent as late underestimate, Overall, adolescent there patients focus US, proportion countries highest population. We on disease adult Registry and will there in based likely we in all of the mind in estimate with drugs, suggests with large patients as EU, This data. and

especially enhancers, important to section, automated will As in vector introduce disease. transduction the of use in including OTL-XXX, my per for for will use VCNs, enhancers us processes. consistently an patients, improvements mentioned process use older previous I The patient, target to less we use manufacturing in transduction which this of of the plan the be achieving while and factor all

the to next place, step process, obtain Frank, registrational Once will we over is to design hard you initiate final teams their updating FDA discuss of The the planned exciting able I registrational to with we pipeline year study. to programs trial as including commercial you. working forward be manufacturing deep our and on. across The the the look have are everything in guidance. and the carries

Frank Thomas

Bobby. Thanks,

This balance offering can many execute access this morning's the very globe. allow million will than and without the multiple second in I us will after the upcoming follow-on U.S. second We on sheet us for facility. to position important in transition to products filings cash the which the results recent highlight briefly potential around accompany the and milestones we three the You the financial capital more Europe, release, need find here. the to strong the credit have $XXX With financial accelerate in markets. our with on quarter a ended to commercializing quarter full puts the press

We into capital expect anticipated and cash that and existing will our the XXXX. operating fund our second expenditures investments of half

one-time a $XXX the approximately XXXX, in expenses to million about year's signed the associated the expenses GSK Last $XXX second XXXX, quarter R&D million, April were same compared in $XX For period charge R&D in we with agreement, million. which totaling XXXX. included of

to period new So and by research as for MPS-X in costs a increase the larger same the primarily was excluding compared license well development driven higher of $XX increased this upfront personnel-related would XXXX. our expenses consideration from year. have million clinical-stage program, and the This charge, as program compared portfolio to last

cash as support costs first for about were our payments quarter $XX which of public for last operations, of significant fund same GSK well three company XXXX of a expenses services. of potential to and million year. increase commercialization due to on higher to late-stage as development in $X of compared expenses, was pay-down inventory which programs. to We accrued the SG&A operations in the included period costs The the million deferred primarily second prepare personnel related the some million XXXX of XXXX, half the to to used transition $XX transaction for

remarks we third by for positions We're of for prepared of my in filings. a This the our In Later year, WAS these in our data summary We've OTL-XXX. the MLD XXXX made in on the ADA-SCID will and Europe substantial providing patients sets our program, released end have of on with end the for progress this be I'll of milestones. evidence releasing well the trial half of two the we BLA registrational data data us rolling three formulations set us to of for X-CGD from for the track of therapies, XXXX. additional registrational the received clinical present programs. of first remaining initiation lead supportive submission these a the with an for the MAA design for also cryopreserved registrational who U.S. year.

next protocol, proposed walk the In design with regulators meet our we trial down CMC steps, registrational to discuss terms of remaining will and work. the complete

ongoing program planned we enrollment newest for in For next. clinical is data OTL-XXX, and this proof-of-concept year treating and MPS-X, trial with have later patients our additional releases a

potential Europe for for and for clinical-stage the remains a program Finally, the year, portfolio. CTA MPS-XA of seventh this of highlighting a our clinical submission a track on initiation in in trial

to believe we will number across of programs the important generated So date. a on offers of build that second our the already XXXX to half clinical milestones continue exciting data

call to now back me the Let Mark. hand

Mark Rothera

Frank. Thanks,

to single cell address vivo As autologous is with or genetic correct in the pediatric experienced we're making tell, that from progress are across some symptoms can we that we now you therapies terrible, lifetime to fundamentally different of clinical the our gene intervention. progression, potentially have have slow that collapsing the about value we excited thought hematopoietic therapy previously anything sustained expression, a diseases. medicine. Instead engraftment of disease characterize underlying treatments regulatory commercialization, chronic are When given defect business. life-threatening stem has we're Ex the how developing And we achieved have of into adequate are of the a we approaching potential and we been great therapies. gene benefit

reality So when of approved, about to by live birthday. see begin do a value, the their and we disease especially not think we with thinking the children do, could about child today XX% if sobering what fifth living our given that rare therapies,

interventions. frequent with these birthdays, So other holidays, many one a other Today, and let's and hospitalization with start milestones of miss child. will child due to the life conditions

And limited. for the children severely to seeking we their lifespans are treat, are

and family, as to And from toll or is placed family comes caring it The toll, a very child the potentially may the opportunity suffering on it's symptoms related On effects disease. the quite about the well. stress a about other more that from an on therapy with real. ill life, well, a completely different hand, back life could scale Think great the as a with emotional have for have by gene child. the But quit to employment. than free their Parents takes child relationships. treated live caused financial

serious family. As transform for opportunity disease, a in the any everyone has also parent with cared of the knows, the particularly child of transform a life a to lives creates parent the child who that to a opportunity

Now, the think of community.

ways. organizations, equipment This homes infrastructure, within a support and the that sick able child. care a and everyone Making contribute that community including they around means they is requires family child better and to employers, significant other all to child civic schools, people schools. the Our for in step as to then in

spent Let's few also and visits, healthcare In would ER some as previously, Specialist vast save system physicians have and would potentially the now and will other opportunity may care. deliver longer providers had interventions treatment they think for hospitalizations, that patients. such be long-term otherwise palliative cases, about no to healthcare where Costly the options the on have a no healthcare required. resources their have procedures also therapy, surgical curative or system. chronic been

us off no And their society are. of broader of better Each who all living impact finally, in We stopped benefits, society. dreaded children we world be within could potentially think be where matter tracks. would a in diseases that

not help society. We the it touch just in working And of for others forward of child, we therapies. healthcare are considering necessary to in that's work So programs branches and responsibility as committed gene to partnership system, all we the how a curative undertaking the and lives and to community, recognize path also value, are with family, the this to ensure potentially the our our but the are out light. sustainable evaluate

your questions. now may for line you time Thank Operator, you and attention open today. the for

Operator

Thank comes [Operator instructions] first with Sachs. you. from Goldman Graig Suvannavejh Our question

is open. line Your

Graig Suvannavejh

two got questions, just please. I've

for the to There thinking. challenges and your around OTL-XXX. or how set on pipeline you, of Zolgensma that us coming are early established have competitors I know pricing, on impact that for of been path we Thank you. the The market, I your first how their up opportunity, and thinking that in wanted that you're you'll know a product. pricing expect kind is with pricing of having data environment. therapies should expect this what down you I newest when but seeing perhaps, frame to could been see September, that data continue gene for with to able might lot at not has question the that attend. to won't has really exciting then what some conference? And be second then next program? we as might critical probably the seeing the given they're you just about of that's that data key do written they've And new

Mark Rothera

questions. Graig, very thank two those you much for

your maybe, then, speak Bobby, and you could forthcoming question I abstract. MPS-X So, SSIEM the will begin, with to

Bobby Gaspar

thanks on MPS-X substrates, meeting we four the primarily, That patients ASGCT Mark this and Graig. SSIEM thanks your be, that CSF, in were we outcome, chemical remember, was that earlier follow-up, IDUA been Yes, very expression enzyme and significant will presentation well and that And data demonstrate given really who encouraging as And patients at well. obviously also presented you sufficient data. had recruited The the reduction follow-up for at the year. periphery also study. we of super-normal know if clinical on in exciting on able patients the longer this in in have to of accumulation the the question, and into with correction both and this by is

in will further presenting more the at we be And follow-up on meeting longer September, patients. those data with and

Mark Rothera

And move then Graig, the second the environment. to maybe, about could on I pricing question

single bring the specific first of know, to guidance important so to of important and into you And be it's therapies, that you can philosophy collapsed to the have on society, pipeline. from do have be I the but can and initiate but life, in we very pricing, if up half thereafter as could administration. it's our these early to benefit now, very guiding the the in or filings families into gene feel that year to like, we the As one-off the remarks, healthcare specific but the curative you medicines, we impact, at potentially we're system. too an in coming those we on more pricing two these, launching enormous which benefit not value clearly value or but detail, or just go conversation lifelong think around earlier our of on next child, looking of two first programs which one and these addressed the that It's therapy right

very resources working with others best the value change full thinking So about being can healthcare really the them we working potential, therapies, to flexible with I of life? think care, how to them child's also about starts for And To eliminating today. stakeholders, think interventions. be payers, and the our in pay think focus what think the methodology our And give about I partnership. time, in in We're of But that's their these. to for talk there system, we we'll it also we substantial the the about with chronic value the their as articulate be with through what's not hospitalizations, so dramatically healthcare surgical able course is needing ER of potential, visits. each

we're each of many, there aspects are work to programs. one that this many our So and for on every to going

GraigSuvannavejh

you good much and very Thank luck.

Mark Rothera

Graig. you, Thank

Operator

from question with next Morgan. Anupam comes Rama Our JP

open. Your line is

Unidentified Analyst

morning, Hey, questions. Thanks good for so guys. Matt on our for Anupam. is much taking This

from couple So just us. a

you First, at on one treated. patient Manchester think I data guys had your three-month quarter MPS-XA, last XXX some colleagues and highlighted that from

broader indications? little team gene your higher So into follow-up Thanks look? to for just pursuing, more not to curious does available and a get wondering the slate just of your some so ahead been that that. additional varied but has in so, and expanding your what starting far beyond if to made we're Secondly, see if on how thoughts much. that level, a just is something myself, so currently you, bit It's too to appetite any therapy, of at get diseases is

Mark Rothera

to it those demonstrating the because, for going But you excited gene second to MPS-XA much to eight that very you as in address MLD condition. generated you, we're remind hematopoietic thank questions. out MPS-X a really field over encouraged neurometabolic stem to the we've the Maybe substantial of whole on question. just program. evidence we're clinical see beginning also the years data can We're coming hand in neurodegenerative therapy by I'll out about Bobby Great, cell a know,

program you really don't you mentioning to great to to question. think, third clinic of I the I the were end year, around Bobby, points any into be. if add by a that have know this a want patient place in specific so the going And is that

Bobby Gaspar

who was formal at no the treated treatment a for treated had then you options treatment was, trial remember, patients therefore, if child special the Yes, available clinical outside Manchester [indiscernible], patient in UK. a that which other the and license, under was who is of so to

So data of that clinical the upcoming engraftment gene and at of cells. months therapy gene-modified and process showed used a that child three actually trial, procedure the enzyme but be through in will expression the the went underwent super-normal encouraging

So something that the that as the at and but soon, look as three clearly, far may up know physicians as will to say, they about And was any I haven't that do publicly. data is as see with months. we'll that in And Manchester child is follow-up forward we shared concerned. but concerned, that. further and for share that us will more as had them just I coming be that we far with that communicating But wait is

CCA looking that been forward trial this trial and And to for you, starting submitted the to remind formal year. and just opening enroll we're that patients has the to later

forward is concerned. look that far you updating as we'll as So to

Mark Rothera

hematopoietic about vivo indications. asked cell of you application stem ex question other the to gene the to Now, therapy broader

significant we're we indications. this approach treatment goes as gene And for in today. saying you've start variety And first we're of of programs remarkable just end the clinic have have in disease me a for year, beyond pipeline we're really Let which in indications, a to showing have or data seven by and some that rare this these remarkable that. options little a seen, potential position, of pre-clinical the many no going therapy by

launching a to medicines and for out we and building arena around see these disease more patients indications in do And the business rare model sustainable rare continuing significant so the through and bring diseases. with really world

to is at platform point, this direction, to that a also around could there indications? I we And we But the when too today. move will applied It's in go should in we'll speculate suspect that be I do direction. letting be early and broader Now, some people yes. to as answer know. view if be, think that whether

Operator

comes Nierengarten with from Securities. Wedbush David Our next question

Your line is open.

David Nierengarten

trial and the I taking When in guess, the think of I for Thanks. set patients, would on clinical look your like to duration, a one trial about of design, regulators just some terms what had you ideal talking Thanks endpoints, X-CGD. dialogue? to question. number

Mark Rothera

the excited the Sure, around It's Clearly, our of world. trial? living that's large this thank with just by thinking in and this an of the as Bobby, we we're look you, Perhaps, for It's at a design development area execution X-CGD to unmet share would population indication. question. some need. relatively you like David, our the high of

Bobby Gaspar

Sure. David, Thanks, Mark, your thanks, question. and for

we the think population. that been we've seen in start in population strongest the adult late about has that where really as study So in we registrational and adolescent actually CGD, And the study efficacy. to want the

strong sustained a I remind shared, seven XX% if So greater evaluable was that patients data the you than previously later. year of six proof-of-concept we've in out neutrophils there of or functional for

oddly line reconstitution on So long-term result as gene defect the a of that one-off therapy.

population. in patients Now, adolescent in fact, six were all those that adult of late the patients -- and that benefited all

So start registrational the sense there. study it to makes

in population addition, large prevalent is proportion that of that the largest is the we've there Now, about. where talked

estimated So anything patients. up X,XXX to we've

disease have which that living as recurrent there. are and of is poor So is with a There liver candidates often a need that they're an chronic transplant, disease unmet CGD with allogeneic There an a of is large population. infections patients the result or lifetime there current lung standard of care. for

design So the talk to the also regulators far clinically at to that. as looking that the course, we'll of is place, go not the endpoints, the but we meaningful have in population the by would be of design and be And confirming registrational that about we'll we're study. by just are concerned, Once addressed endpoints endpoints chemical best as study.

David Nierengarten

to there transplants, the grafts Maybe adolescent patient young where, Would obviously, are younger and patients. a in be quick better a that follow-up. younger We've little population, in multiple understanding population prevalent in a is to the late by expand tolerated instances bit adult? any seen and plans

Bobby Gaspar

might why younger number reason enough as of a that group to what that shouldn't to who poor just that we the condition, be look for age to had move the about is reasons we so follow-up population be patients hope work at biological the that that study, to this very able in recap, into we've the pediatric are with evaluate in had Sure, been do patients a so evaluate again will talked is stage. later to And of engraftment to no we'll at We in limited But patients, able this there's and to previously haven't patient evaluable in why case. able course, be XX-month far. that. treatment more detail, further do one

Operator

would closing like questions Thank further at you to Rothera over showing no remarks. Mark for and this time. turn I back call I'm the

Mark Rothera

Thank for you joining today. all the call

mission I year we're up building delivering gear half again of programs. patients of the a we deal the approved, portfolio administration. tremendous bringing lifetime we our curative I'm the year. to through benefit our one toward rich look and accomplished of hope the also if to in we single of to for of the a our a joining additional great therapies believe a day. forward potentially this for to first across and while progress team making provide regulatory next have this progress demonstrated, of And has around half filings in us all what patients year. Thank as two and potential you milestones the pre-clinical We after, very world. therapies clinical sharing that of proud have year As great We're momentum second our

Operator

have for Ladies joining concludes day. and wonderful a conference. today's and Thank gentlemen, you

Renee Leck	Director, Investor Relations
Mark Rothera	President, Chief Executive Officer
Bobby Gaspar	Chief Scientific Officer
Frank Thomas	Chief Financial Officer and Chief Business Officer
Graig Suvannavejh	Goldman Sachs
Anupam Rama	JP Morgan
David Nierengarten	Wedbush Securities

Orchard Therapeutics (ORTX) 11 Aug 192019 Q2 Earnings call transcript